Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cytokine. 2020 Oct 28;137:155334. doi: 10.1016/j.cyto.2020.155334

Figure 2. Anti-inflammatory effects of precursor mouse IL-38 compared to N-terminus processed IL-38.

Figure 2.

A. Mouse BMDC were incubated with precursor recombinant mouse IL-38 (1–152) or mouse IL-38 (3–152) for one hour followed by stimulation with LPS (10 ng/mL). After 24 hours, the supernatants were assayed for IL-6. The data are shown as mean ±SEM, *p < 0.05, n=6.B. Mouse BMDCs were incubated with precursor or 3–152 recombinant human IL-38 for one hour and then stimulated with LPS (10 ng/mL). After 24 hours, the supernatants were assayed for IL-6. The data are shown as mean ±SEM, *p < 0.05, n=5 per group. In A, the dose-escalation starts a 0.1 ng/mL and increased by a factor of 10 to 1000 ng/mL. In B, the dose-escalation starts a 0.01 ng/mL and increased by a factor of 10 to 100 ng/mL.